|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INSIG1 |
Gene summary for INSIG1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INSIG1 | Gene ID | 3638 |
| Gene name | insulin induced gene 1 | |
| Gene Alias | CL6 | |
| Cytomap | 7q36.3 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | A4D2M9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3638 | INSIG1 | LZE2T | Human | Esophagus | ESCC | 2.88e-04 | 7.22e-01 | 0.082 |
| 3638 | INSIG1 | LZE4T | Human | Esophagus | ESCC | 2.76e-03 | 5.46e-01 | 0.0811 |
| 3638 | INSIG1 | LZE8T | Human | Esophagus | ESCC | 7.53e-03 | -1.77e-01 | 0.067 |
| 3638 | INSIG1 | LZE20T | Human | Esophagus | ESCC | 6.94e-07 | 3.14e-02 | 0.0662 |
| 3638 | INSIG1 | LZE24T | Human | Esophagus | ESCC | 2.17e-05 | 6.54e-01 | 0.0596 |
| 3638 | INSIG1 | LZE21T | Human | Esophagus | ESCC | 1.74e-03 | 8.17e-01 | 0.0655 |
| 3638 | INSIG1 | LZE6T | Human | Esophagus | ESCC | 7.89e-04 | -2.89e-01 | 0.0845 |
| 3638 | INSIG1 | P2T-E | Human | Esophagus | ESCC | 8.61e-04 | 2.69e-01 | 0.1177 |
| 3638 | INSIG1 | P4T-E | Human | Esophagus | ESCC | 1.44e-34 | 1.94e+00 | 0.1323 |
| 3638 | INSIG1 | P5T-E | Human | Esophagus | ESCC | 5.11e-34 | 1.71e+00 | 0.1327 |
| 3638 | INSIG1 | P8T-E | Human | Esophagus | ESCC | 8.58e-06 | 3.81e-01 | 0.0889 |
| 3638 | INSIG1 | P9T-E | Human | Esophagus | ESCC | 8.46e-10 | 7.51e-01 | 0.1131 |
| 3638 | INSIG1 | P10T-E | Human | Esophagus | ESCC | 1.25e-40 | 1.86e+00 | 0.116 |
| 3638 | INSIG1 | P11T-E | Human | Esophagus | ESCC | 1.23e-04 | 9.38e-01 | 0.1426 |
| 3638 | INSIG1 | P12T-E | Human | Esophagus | ESCC | 3.20e-07 | 3.15e-01 | 0.1122 |
| 3638 | INSIG1 | P15T-E | Human | Esophagus | ESCC | 3.38e-27 | 1.46e+00 | 0.1149 |
| 3638 | INSIG1 | P17T-E | Human | Esophagus | ESCC | 1.27e-02 | -1.90e-02 | 0.1278 |
| 3638 | INSIG1 | P20T-E | Human | Esophagus | ESCC | 9.48e-16 | 8.70e-01 | 0.1124 |
| 3638 | INSIG1 | P21T-E | Human | Esophagus | ESCC | 6.17e-19 | 1.43e+00 | 0.1617 |
| 3638 | INSIG1 | P22T-E | Human | Esophagus | ESCC | 4.16e-23 | 9.29e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00329333 | Liver | Cirrhotic | SREBP signaling pathway | 9/4634 | 15/18723 | 3.88e-03 | 2.10e-02 | 9 |
| GO:00069912 | Liver | Cirrhotic | response to sterol depletion | 10/4634 | 18/18723 | 5.00e-03 | 2.59e-02 | 10 |
| GO:00510514 | Liver | Cirrhotic | negative regulation of transport | 141/4634 | 470/18723 | 5.06e-03 | 2.62e-02 | 141 |
| GO:00454442 | Liver | Cirrhotic | fat cell differentiation | 73/4634 | 229/18723 | 8.57e-03 | 3.97e-02 | 73 |
| GO:00423043 | Liver | Cirrhotic | regulation of fatty acid biosynthetic process | 20/4634 | 49/18723 | 9.60e-03 | 4.35e-02 | 20 |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:003238621 | Liver | HCC | regulation of intracellular transport | 231/7958 | 337/18723 | 1.99e-22 | 3.40e-20 | 231 |
| GO:003315721 | Liver | HCC | regulation of intracellular protein transport | 165/7958 | 229/18723 | 8.37e-20 | 1.15e-17 | 165 |
| GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
| GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
| GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
| GO:003286821 | Liver | HCC | response to insulin | 172/7958 | 264/18723 | 7.14e-14 | 4.23e-12 | 172 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
| GO:003286921 | Liver | HCC | cellular response to insulin stimulus | 137/7958 | 203/18723 | 4.69e-13 | 2.44e-11 | 137 |
| GO:000690021 | Liver | HCC | vesicle budding from membrane | 53/7958 | 61/18723 | 7.38e-13 | 3.80e-11 | 53 |
| GO:004343422 | Liver | HCC | response to peptide hormone | 247/7958 | 414/18723 | 9.55e-13 | 4.77e-11 | 247 |
| GO:007137521 | Liver | HCC | cellular response to peptide hormone stimulus | 179/7958 | 290/18723 | 2.54e-11 | 9.88e-10 | 179 |
| GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
| GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INSIG1 | SNV | Missense_Mutation | novel | c.698N>A | p.Val233Asp | p.V233D | O15503 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INSIG1 | deletion | In_Frame_Del | c.776_778delTGG | p.Val259del | p.V259del | O15503 | protein_coding | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |||
| INSIG1 | SNV | Missense_Mutation | c.108G>C | p.Glu36Asp | p.E36D | O15503 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| INSIG1 | SNV | Missense_Mutation | novel | c.349N>A | p.Glu117Lys | p.E117K | O15503 | protein_coding | tolerated(0.1) | probably_damaging(0.996) | TCGA-VS-A9V0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| INSIG1 | SNV | Missense_Mutation | rs780785188 | c.769N>A | p.Val257Ile | p.V257I | O15503 | protein_coding | tolerated(0.38) | probably_damaging(0.995) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| INSIG1 | deletion | In_Frame_Del | novel | c.276_278delNNN | p.Phe92_Ser93delinsLeu | p.F92_S93delinsL | O15503 | protein_coding | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| INSIG1 | SNV | Missense_Mutation | novel | c.737N>A | p.Ser246Tyr | p.S246Y | O15503 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| INSIG1 | SNV | Missense_Mutation | novel | c.757T>G | p.Phe253Val | p.F253V | O15503 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| INSIG1 | SNV | Missense_Mutation | novel | c.409N>A | p.Ala137Thr | p.A137T | O15503 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| INSIG1 | SNV | Missense_Mutation | novel | c.293N>G | p.Leu98Arg | p.L98R | O15503 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |